Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Criteria developed by Cancer Control and HTA Agencies

From: International lessons in new methods for grading and integrating cost effectiveness evidence into clinical practice guidelines

Cancer control initiatives National HTA agencies
National cancer control initiative (Australia)
 Health gain-disability adjusted life years (DALYs)
 (Vertical) equity-reducing inequalities in mortality rates in vulnerable populations
 Size of health burden-disease burden in DALYs and cost to health system
 Acceptability and feasibility
NICE (England and Wales)
 Clinical effectiveness
 Cost-effectiveness
 Feasibility and impact
 Equity and equality
 Acceptability and appropriateness
British Columbia cancer control decision-makers (Canada)
 Health gain-quality adjusted life years (QALYs)
 Resource impact-budget constraints
 Resource impact- resource constraints
 Availability/advisability of alternatives
Pharmaceutical benefits advisory committee (Australia)
 Gap in current coverage
 Cost-effectiveness
 Effectiveness and safety
 Community need